Su1157 Antibiotic Use Increases the Abundance of Potential Pathogenic Gastric Bacteria in Children Taking Proton Pump Inhibitors

polymorphism and widely used in the eradication, rabeprazole (RPZ) and esomeprazole (EPZ). Patients and methods: This was a prospective, multi-centered, non-blinded, randomized clinical trial. We conducted tests such as rapid urease test or urea breath test (UBT) in patients confirmed of having gastric/duodenal ulcers or chronic atrophic gastritis by esophagogastroduodenoscopy (EGD) to find the infection status of H. pylori, and 147 positive patients were enrolled. Gastric juice was collected to see the CYP2C19 polymorphism and CAM resistant rate during EGD. Patients were randomized into either RPZ 10 mg bid + AMPC 750 mg bid + CAM 200 mg bid for 7 days group or EPZ 20 mg bid + AMPC 750 mg bid + CAM 200 mg bid for 7 days group. Background factors (age, gender, height, weight, BMI, smoking, alcohol, concomitant drugs, baseline disease) were studied, and eradication was evaluated by UBT at least four weeks after the end of the eradication therapy. Results: The evaluation subject was 147 patients, and a background factors did not have the significant difference between both groups (p>0.05). The eradication rate in RPZ group was 68.4% (52/76) while it of EPZ group was 77.5% (55/71), with no significant difference between groups (p=0.27). Overall CAM resistant rate 15% (22/147). As for the eradication success rate of CAM resistant, the eradication rate in RPZ group was 40.0% (2/5) while it of EPZ group was 52.9% (9/17), with no significant difference between groups (p>0.05). In all, the ratio distribution of CYP2C19 genotype was RM 31%(19/61), intermediate metabolizers (IM) 54 %( 33/61), poor metabolizers (PM) 15%(9/61). Between the two groups, there was no significant difference in the success rate of eradication by each genotype (p>0.05). Conclusions: In the eradication rate of H. pylori by the triple therapy, RPZ and EPZ were comparable. Also, in the examination by clarithromycin resistance and CYP2C19 genotype, the eradication rate of both drugs was equivalent.